Nutra Pharma Corp. reported its financial results for the third quarter ending September 30, 2024, revealing a net sales figure of $74,994, a 45% increase from $51,612 in the same period last year. For the nine months ending September 30, 2024, total net sales reached $164,436, slightly up from $158,532 in the prior year. Despite the increase in revenue, the company reported a net loss of $260,683 for the quarter, compared to a loss of $278,486 in the third quarter of 2023. The nine-month net loss also improved to $1,054,756 from $1,150,292 year-over-year.

The company’s balance sheet as of September 30, 2024, showed total assets of $558,838, a decrease from $640,397 at the end of 2023. Current liabilities increased to $15,213,257 from $14,171,637, primarily due to higher accounts payable and accrued expenses. Nutra Pharma's stockholders' deficit widened to $14,819,564, compared to $13,768,308 at the end of the previous fiscal year, reflecting ongoing financial challenges and accumulated losses.

Operationally, Nutra Pharma continues to face significant challenges, particularly with its reliance on a single customer, Avini Health, which accounted for approximately 31% of total revenues in the third quarter of 2024, down from 63% in the same quarter of 2023. This decline is attributed to Avini beginning to manufacture its own products, which is expected to further impact Nutra Pharma's revenue streams. The company has also reported an increase in accounts receivable, which stood at $23,149, up from $22,433 at the end of 2023, indicating potential cash flow issues.

Looking ahead, Nutra Pharma has expressed concerns regarding its ability to continue as a going concern, citing a working capital deficit of $14,902,502 and the need for additional financing to sustain operations. The company is exploring various funding options, including debt and equity, but acknowledges the uncertainty surrounding its ability to secure necessary capital. The management's outlook remains cautious, emphasizing the need to increase sales of its pain relief products to achieve operational viability and repay obligations as they come due.

About NUTRA PHARMA CORP

Nutra Pharma is a biopharmaceutical company specializing in drug discovery, development, and commercialization of treatments for autoimmune, viral, and pain-related conditions. It offers over-the-counter pain relievers, homeopathic products, and drug candidates targeting neurological and infectious diseases. The company focuses on innovative therapies, strategic licensing, and international expansion, leveraging proprietary technology and regulatory designations like Orphan Drug status to address serious health conditions.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov